SEARCH

SEARCH BY CITATION

Keywords:

  • Cardiovascular;
  • Echocardiography;
  • Heart failure;
  • Hemodynamics

Abstract

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

Background: Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease.

Hypothesis: Pimobendan decreases the severity of PHT measured echocardiographically and improves quality-of-life scores. Changes in N-terminal probrain natriuretic peptide (NT-proBNP) concentrations will reflect improvement in severity of PHT.

Animals: Ten client-owned dogs with peak tricuspid regurgitant flow velocity (TRFV) ≥3.5 m/s.

Methods: Prospective short-term, double-blinded, crossover design, with a long-term, open-label component. Short term, dogs were randomly allocated to receive either placebo or pimobendan (0.18–0.3 mg/kg PO q12 h) for 14 days. After a 1-week washout, they received the alternative treatment for 14 days, followed by pimobendan open-label for 8 weeks.

Results: Short-term comparison: peak TRFV decreased in all dogs on pimobendan compared with placebo from a median of 4.40 (range, 3.2–5.6) to 3.75 (range, 2.4–4.8) m/s (P < .0001). NT-proBNP concentration decreased after treatment with pimobendan from a median of 2,143 (range, 450–3,981) to 1,329 (range, 123–2,411) pmol/L (P= .0009). All dogs improved their quality-of-life score (P= .006). In the long-term comparisons, peak TRFV decreased in all dogs from a median of 4.28 (range, 3.5–5.7) to 3.52 (range, 2.4–5.0) m/s (P < .0001). No significant changes in NT-proBNP or quality-of-life scores were detected.

Conclusions and Clinical Importance: Pimobendan lowered severity of measurable PHT, improved quality-of-life scores, and decreased NT-proBNP concentrations short-term. Long term, only the reduction in TRFV was maintained.

Abbreviations:
FETCH

functional evaluation of cardiac health

LA

left atrial

LA/Ao

left atrium to aortic root ratio

LV

left ventricular

MVD

myxomatous mitral valve disease

NT-proBNP

amino terminal probrain natriuretic peptide

PAP

pulmonary arterial pressure

PDE

phosphodiesterase

PHT

pulmonary hypertension

TR

tricuspid regurgitation

TRFV

tricuspid regurgitant flow velocity

Pulmonary hypertension (PHT) is defined as an increase in pulmonary arterial pressure (PAP). Systolic PAP >30 mmHg or mean PAP >20 mmHg confirms the diagnosis of PHT.1–9 Three mechanisms may contribute to increased PAP: increased left atrial (LA) pressure, increased pulmonary blood flow, and increased pulmonary vascular resistance. Pulmonary venous hypertension, also termed postcapillary PHT, reflects increased PAP secondary to passive increases in LA pressure. Although idiopathic PHT is common in humans, PHT in dogs usually is associated with an underlying abnormality such as congenital cardiac disease, left heart failure, chronic pulmonary disease, heartworm infestation, or pulmonary thromboembolic disease.1,2,9,10

Brain natriuretic peptides are hormones produced in response to states of circulating volume overload, and act as antagonists of the renin-angiotensin system. In healthy humans and dogs, circulating forms of BNP probably are derived primarily from the atria, but under pathological conditions, production of BNP increases substantially in both the atria and ventricles.11–13 Cleavage of the prohormone brain natriuretic peptide produces an amino-terminal fragment denoted amino terminal probrain natriuretic peptide (NT-proBNP), and a carboxy-terminal end comprising active BNP.11,13 Numerous diseases that result in right heart dysfunction in humans are associated with increased NT-proBNP concentrations.14,15 Veterinary studies have demonstrated the utility of NT-proBNP concentrations in distinguishing animals with heart disease from normal animals and those with primary respiratory disease.16–18 Additionally, recent information suggests dogs with PHT have NT-proBNP concentrations that are significantly increased compared with dogs with solely primary respiratory disease.a

Pimobendanb is an oral inotropic drug with phosphodiesterase 3 (PDE3) inhibitory and calcium sensitizing effects. Left heart catheterization studies in normal dogs and dogs with heart failure have documented that pimobendan caused a marked decrease in left ventricular (LV) end-diastolic pressure and pulmonary capillary wedge pressure.19–22 Additionally, pimobendan caused potent vasodilatation of the systemic vasculature in dogs.21,22 However, the effect of pimobendan on canine pulmonary vasculature has not been reported. Case reports in humans receiving pimobendan showed promising results in the therapy of primary PHT, in PHT secondary to chronic emphysema, and in a patient with dilated cardiomyopathy and chronic obstructive pulmonary disease.23–27

Effective treatment of severe PHT is difficult, because many of the underlying causes of PHT are progressive and result in irreversible changes in the pulmonary vasculature. Identification and treatment of the underlying cause (eg, closure of left-to-right shunt, treatment of heartworm disease) is optimal. Common symptomatic therapies utilized include oxygen treatment, bronchodilators, vasodilators, and diuretics.4 Sildenafil, a PDE5 inhibitor, has been used to treat dogs with PHT, and is regarded as a standard of care in veterinary medicine.28,29 In 1 retrospective study, sildenafil did not significantly lower measurable PHT, but did result in clinical improvement.29 Pimobendan has been advocated as a therapy for dogs with PHT, but its use has not been critically examined.30

The purpose of this study was to describe the clinical outcome and change in the severity of PHT in dogs with myxomatous mitral valve disease (MVD) treated with pimobendan.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

Study Animals

Client-owned dogs with naturally occurring, moderate-to-severe PHT that presented to the University of Missouri, Veterinary Medical Teaching Hospital between May 2006 and September 2007 were eligible. Dogs with a tricuspid regurgitation (TR) jet yielding a peak tricuspid regurgitant flow velocity (TRFV) ≥3.5 m/s were considered candidates. The presence of pulmonic stenosis was exclusionary. Other exclusionary criteria included evidence of any systemic disorder such as renal or hepatic disease likely to have prevented completion of the protocol or to have interfered with metabolism of medication. Additionally, dogs with renal disease and azotemia have been shown to have increased NT-proBNP concentrations.31 Dogs were heartworm antigen negative and receiving heartworm prophylaxis. Pre-existing therapy with cardiac medications was allowed, excluding other PDE inhibitors (eg, theophylline or sildenafil). Dogs in heart failure were stabilized before enrollment.

Nine normal dogs were recruited to serve as negative controls for comparison of NT-proBNP concentrations. Control dogs had normal physical and echocardiographic examinations.

Study Design

The study was conducted as a short-term, placebo-controlled, double-blinded, randomized, crossover design, with a long-term, open-label component. Dogs were assigned to initial therapy by a random assignment table. Dogs were enrolled with informed client consent, and the study was approved by the Animal Care and Use Committee at the University of Missouri.

The dogs were examined on days 0, 14, 21, 35, and 91. In the 35-day short-term treatment period, dogs were randomly allocated to receive either placebo or pimobendan (mean dose, 0.25 mg/kg; range, 0.18–0.30 mg/kg) PO q12 h for 14 days. Owners were instructed to give the treatment 1 hour before, or 2 hours after feeding. Owners and the investigator performing the echocardiograms were blinded to the group assignment. All measurements were repeated after 14 days, and again after a 1-week washout (day 21). Dogs then received the alternative treatment for 14 days, and measurements were repeated on day 35. After the 35-day crossover period, all dogs received pimobendan for 8 weeks, and all variables were measured on day 91.

Echocardiography

A single echosonographer performed all examinations (KJA). Two-dimensional, M-mode, and Doppler echocardiographic examinations were performed utilizing standard views in unsedated dogs.32 Three to 5 measurements were averaged for each variable. A peak TRFV ≥3.5 m/s, which is equivalent to a peak TR pressure gradient ≥50 mmHg by the modified Bernoulli equation (ΔP= 4 × velocity2) was considered indicative of moderate to severe PHT. Pulmonary velocity flow profiles were obtained by pulsed-wave Doppler, with the sampling gate positioned at the pulmonic valve. Systolic time intervals were obtained for pulmonary velocity acceleration and ejection time by a simultaneously recorded electrocardiograph (ECG), and were not corrected for heart rate.33,34

Clinical Evaluation

Heart rate, rectal temperature, respiratory rate, and body weight were recorded. A standard 6-lead ECG was obtained to determine the underlying rhythm, assess for arrhythmias, and calculate the mean electrical axis.35 Thoracic radiographs were obtained at each visit, and a board-certified radiologist provided additional comments on the pulmonary parenchyma. Vertebral heart size scoring was measured using a reference range of 8.5–10.5.36 Thoracic radiographs were assigned a pulmonary edema score graded as follows: 1—no edema, 2—mild interstitial density, 3—moderate interstitial density, 4—alveolar pattern, and 5—severe consolidation.37 Indirect systolic blood pressure was determined as the mean of 3 readings with an ultrasonic Doppler flow detector. The quality-of-life scoring system (functional evaluation of cardiac health [FETCH] questionnaire) was completed by the owner at each visit.38

Hematologic Evaluation

Serum biochemistry profiles were performed by the University of Missouri's Veterinary Medical Diagnostic Laboratory. For measurement of NT-proBNP, blood was placed into chilled-EDTA collection tubes. Within 20 minutes of collection, the blood was centrifuged for 5 minutes at 1,720 ×g and the supernatant frozen at −80°C. Samples were batched for analysis and submitted frozen on dry ice to the testing laboratoryc for assay, by previously described methodology.17

Statistical Analysis

All calculations and statistical analyses were performed with standard commercial software.d,e Because of the small number of study subjects, values are presented as median and range. Results during the short-term phase were analyzed by a 2-period crossover design, with factors treatment, treatment sequence, and (random) dog. To ensure that treatment order did not affect the short-term results, the analysis first tested for a significant sequence effect. Treatment order was not significant, and therefore the effect of pimobendan therapy was assessed next by the appropriate F-test and corresponding P-value. Comparison of baseline to day 91 results was performed by the Wilcoxon signed-rank test. The Mann-Whitney rank-sum test was used for comparisons between the PHT and control group. P values < .05 were considered significant.

Results

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

Thirteen dogs met the study inclusion criteria. One dog withdrew from the study because of the owner relocating, and was excluded from analysis. One dog died between days 35 and 91, and was analyzed only in the short-term cross-over segment of the study. There were too few dogs (n = 2) with precapillary PHT to permit statistical analysis, and therefore these dogs were excluded from analysis. However, a brief report of their results is provided for descriptive purposes. The remaining 10 dogs all had chronic degenerative mitral valve disease and were receiving therapy for heart failure.

Six dogs were spayed females and 4 were castrated males. Breeds included Shetland Sheepdog (n = 2), Boston Terrier (n = 1), Cocker Spaniel (n = 1), Bull Terrier (n = 1), Dalmatian (n = 1), Papillon (n = 1), Chihuahua (n = 1), Terrier mix (n = 1), and Labrador mix (n = 1). The median age was 12.8 years (range, 8–14.9 years); median weight was 11.1 kg (range, 4.7–27.5 kg). Clinical signs included cough (n = 10), collapse or syncope (n = 8), respiratory distress (n = 3), and ascites (n = 2). Necropsies were not obtained in any dog.

Medications administered during the study period included furosemide (n = 10), enalapril (n = 9), spironolactone (n = 3), hydrocodone (n = 3), omega-3 fatty acid/fish oil supplementation (n = 2), benazepril (n = 1), diltiazem (n = 1), digoxin (n = 1), fluticasone propionate (n = 1), carprofen (n = 1), deracoxib (n = 1), thyroxine (n = 1), taurine (n = 1), carnitine (n = 1), metronidazole (n = 1), and dan shen (n = 1). The minimum effective dosage of furosemide was prescribed at all times and reassessed at each visit. Two dogs demonstrated clinical and radiographic evidence of progressive heart failure on days 14 and 35, necessitating increases in furosemide dosage at both visits. No changes in treatment with any other cardiac drugs were permitted with 1 exception. Because of recurring diarrhea, 1 dog had digoxin discontinued and the diltiazem dosage increased during the open-label period. No owners reported complications associated with pimobendan.

The characteristics of 9 normal control dogs were compared with the baseline of the 10 dogs with PHT. Control subjects were significantly younger (median, 5 years; range, 0.5–7 years; P < .0001), and heavier (median, 19.8 kg; range, 13.8–32.4 kg; P = .02) than dogs with PHT. The baseline NT-proBNP concentration in patients with PHT (median, 1,799 pmol/L; range, 289–3,723 pmol/L) was significantly higher than that of control dogs (median, 373 pmol/L; range, 209–738 pmol/L; P= .0013).

All dogs showed a decrease in peak TRFV while receiving pimobendan treatment (median, 3.75 m/s; range, 2.4–4.8 m/s) compared with placebo (median, 4.4 m/s; range, 3.2–5.6 m/s) in the short-term cross-over phase of the study (P < .0001). Peak TRFV also decreased significantly in all dogs from day 0 (median, 4.28 m/s; range, 3.5–5.7 m/s) to day 91 (median, 3.52; range, 2.4–5.0; P < .0001; Fig 1).

image

Figure 1.  Box plots depicting the change in peak tricuspid regurgitant flow velocity (m/s) in 10 dogs affected with pulmonary hypertension secondary to mitral valve disease. There was a significant reduction in the flow velocity in dogs receiving pimobendan versus placebo for 14 days (*P < .0001). There was also a significant decrease from day 0 to day 91, after 8 weeks of open-label therapy (#P < .0001). In each box, the central horizontal line indicates the median value; the box includes the 25th–75th percentiles, the whiskers represent the 10th and 90th percentiles, and circles indicate outliers that lie outside the 10th and 90th percentiles.

Download figure to PowerPoint

The summed quality-of-life scores varied widely among patients, with a lower score indicating the owner's perception of a better quality of life. All dogs experienced a decrease in their summed quality-of-life score on pimobendan (median, 15; range, 1–35) compared with placebo (median, 25.5; range, 2–49; P= .006). However, no significant change in the quality-of-life score was found when comparing baseline (median, 22; range, 3–58) to day 91 (median, 17; range, 1–41; P= .13; Fig 2).

image

Figure 2.  Box plots depicting summed quality of life scores in 10 dogs affected with pulmonary hypertension secondary to myxomatous mitral valve disease receiving pimobendan versus placebo (*P= .006). There was no significant change long term (P= .11). Low values indicate minimal clinical signs, and higher values indicate increasing severity of signs. See Figure 1 for explanation of box plots.

Download figure to PowerPoint

Concentrations of NT-proBNP decreased significantly with pimobendan therapy (median, 1,329 pmol/L; range, 123–2,411 pmol/L) compared with placebo (median, 2,143 pmol/L; range, 450–3,981 pmol/L; P= .0009). However, no significant changes in NT-proBNP concentrations were found in the long-term comparison between baseline (median, 1,799; range, 289–3,723 pmol/L) and day 91 (median, 984 pmol/L; range, 489–3,526 pmol/L; P= .12; Fig 3).

image

Figure 3.  Box plots depicting N-terminal probrain natriuretic peptide (NT-proBNP) concentrations (pmol/L) in study dogs affected with pulmonary hypertension secondary to myxomatous mitral valve disease. Pimobendan therapy resulted in a significant decrease in the NT-proBNP concentrations compared with placebo in the short-term comparison (*P= .0009). There was no significant change long term (P= .12). See Figure 1 for explanation of box plots.

Download figure to PowerPoint

Results for selected physical examination, echocardiographic, and hematologic findings were compared for the short-term phase (Table 1) and between baseline and day 91 (Table 2). The only significant change in physical examination findings was a decrease in heart rate with pimobendan treatment compared with placebo (P= .04). Therapy with pimobendan resulted in significant improvement in some of the echocardiographic parameters of systolic function and markers of preload. In the short-term phase, the LV internal dimension in systole (P < .001), LV dimension in diastole (P= .01), and the LV shortening area (P= .02) improved. In the long-term comparison, the LV internal dimension in systole (P= .02) and the LV shortening area (P= .04) remained significantly decreased. There were no significant alterations in the LA dimension or LA to aortic root ratio at any time. There were no changes in the Doppler-derived systolic time intervals of pulmonary artery flow during the short-term phase. However, there were small but significant increases in the pulmonary artery acceleration and ejection times at day 91. There was no significant change in the pulmonary edema score at any time. The VHS decreased significantly with pimobendan therapy during the short-term phase (P= .003), but this was not maintained long term (P= .26). There was no significant change in the mean electrical axis or discernable abnormal rhythm development with pimobendan therapy.

Table 1.   Comparison of selected physical and diagnostic test results in the short-term comparison while receiving either a placebo or pimobendan therapy.
VariablePlaceboPimobendanP value
  • Values presented as median (range).

  • *

    P < .05 significant.

  • LV, left ventricular; PA, pulmonary artery.

Heart rate (bpm)133.5 (100–176)125.5 (99–148).04*
Respiratory rate (rpm)30 (16–59)28 (24–59).52
Systolic blood pressure (mmHg)113.8 (80–147)113.3 (77–132).29
Vertebral heart size12.4 (11.2–13.0)12.2 (11.0–13.0).003*
Mean electrical axis (degrees)76 (48–161)82.5 (55–239).23
Blood urea nitrogen (mg/dL)34 (16–56)31 (18–70).95
Creatinine (mg/dL)1.1 (0.9–2.0)1.1 (0.8–1.6).29
Alanine aminotransferase (U/L)49.5 (33–277)37 (18–244).43
Alkaline phosphatase (U/L)88.5 (19–955)143 (15–590).75
Total bilirubin (mg/dL)0.2 (0.1–0.4)0.2 (0.1–0.5).54
PCV (%)47 (36–58)45.5 (39–61).43
PA acceleration time (ms)47 (27–105)46 (30–101).62
PA ejection time (ms)147 (112–298)142 (92–337).79
PA acceleration time/ejection time0.31 (0.23–0.34)0.33 (0.20–0.40).46
Left atrial diameter (cm)2.82 (1.77–4.9)2.58 (2.14–4.81).15
Left atrial diameter/aortic root1.90 (1.19–2.57)1.71 (1.28–2.40).31
LV diastolic diameter (cm)3.56 (2.47–6.75)3.36 (1.87–6.23).01*
LV systolic diameter (cm)1.64 (1.29–4.33)1.38 (0.63–3.97)<.001*
Fractional shortening (%)48.1 (33.2–61.8)54.1 (29.8–67.2).051
LV shortening area (%)62.8 (46.3–76.6)65.8 (47.0–81.3).02*
Table 2.   Comparison of selected physical and diagnostic test results in the long-term comparison between day 0 (before pimobendan therapy) and day 91 (after pimobendan therapy).
VariableDay 0Day 91P value
  • Values presented as median (range).

  • *

    P < .05 significant.

  • LV, left ventricular; PA, pulmonary artery.

Heart rate (bpm)131 (86–176)128 (95–191).86
Respiratory rate (rpm)24 (20–59)28 (24–59).67
Systolic blood pressure (mmHg)110.7 (85–131)115.7 (77–144).31
Vertebral heart size12 (11.2–13)12.4 (11.2–13).26
Mean electrical axis (degrees)84 (54–263)82 (57–260).95
Blood urea nitrogen (mg/dL)36 (11–60)33 (23–98).64
Creatinine (mg/dL)1.0 (0.9–1.6)1.0 (0.8–1.6).76
Alanine aminotransferase (U/L)70 (21–179)55 (25–246).59
Alkaline phosphatase (U/L)167 (16–1254)129 (15–1209).11
Total bilirubin (mg/dL)0.2 (0.1–0.3)0.2 (0.1–0.4).58
PCV (%)46 (31–56)44 (41–57).81
PA acceleration time (ms)39.4 (29–53.2)43.6 (37.3–62.1).017*
PA ejection time (ms)138 (124–167)150 (131–180).049*
PA acceleration time/ejection time0.28 (0.23–0.40)0.32 (0.25–0.40).36
Left atrial diameter (cm)2.67 (1.88–4.91)2.4 (1.96–5.14).19
Left atrial diameter/aortic root1.59 (1.18–2.61)1.75 (1.17–2.58).64
LV diastolic diameter (cm)3.50 (2.40–6.60)3.26 (2.49–6.40).37
LV systolic diameter (cm)1.54 (1.20–4.37)1.39 (1.02–4.26).02*
Fractional shortening (%)50.2 (32.4–65.2)54.9 (33.5–64.4).31
LV shortening area (%)62.4 (46.6–76)69.1 (49.8–79.9).04*

Nine of the PHT dogs had died or were euthanized after completing the study. One dog was still alive at the time of manuscript submission. The median survival was 352 days (range, 101 to > 874 days).

Two dogs had PHT attributed to pulmonary disease; both were spayed females (a 13.7-year-old West Highland White Terrier and a 12.4-year-old Boston Terrier). Because of the low number of cases, these dogs were excluded from statistical analysis. Their long-term (day 0 versus 91) response to pimobendan is provided briefly for descriptive purposes. In 1 dog, TRFV decreased from 4.0 to 3.9 m/s, NT-proBNP decreased from 661 to 508 pmol/L, and quality-of-life score remained unchanged at 41. In the other dog, TRFV increased from 4.2 to 4.6 m/s, NT-proBNP increased from 1,635 to 2,272 pmol/L, and quality-of-life score increased from 24 to 45.

Discussion

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

In this study of dogs with naturally occurring, moderate-to-severe PHT secondary to degenerative mitral valve disease, pimobendan therapy was well tolerated when added to standard congestive heart failure therapy. This supports previous studies demonstrating a positive effect of pimobendan in mitral valve disease.39

Peak TRFV was the sole determinant used to diagnose PHT echocardiographically in this study. Optimal parallel alignment with the peak tricuspid regurgitant jet requires skill and is vital for accuracy, as is patient cooperation.1,10 This method allows rapid, noninvasive estimation of pulmonary pressure, through application of the modified Bernoulli equation. In the absence of pulmonic stenosis, the right ventricular to right atrial pressure gradient, when added to the clinically estimated right atrial pressure, can be used to estimate PAP. However, because of certain limitations of the Bernoulli equation, peak TRFV alone was used for statistical analysis. The calculated pressure gradient ignores initial flow velocity, the contribution of flow acceleration, and viscous friction.40 Furthermore, because the Bernoulli equation transforms the data by squaring the flow velocity and multiplying it by 4, there is the potential to magnify small, nonsignificant changes and alter conclusions about the efficacy of treatment. Baseline TRFV was higher than would be expected in these dogs if the increase was solely because of passive increases in LA pressure. However, an increase in pulmonary vascular resistance may accompany long-standing increases in LA pressure, producing a mixed hemodynamic response.5,6,41

The therapeutic benefits of pimobendan for PHT are hypothesized to be because of pulmonary vasodilatation, decreased LA filling pressures, peripheral vasodilatation, and increased right and left ventricular contractility. The improvements seen in the echocardiographic measures of contractility were predictable with the use of a positive inotrope. An inotropically mediated reduction in left ventricular end-diastolic pressure potentially could have accounted for the decrease in TRFV seen in this study. The effect of pimobendan on pulmonary vascular resistance cannot be determined with the model used. Invasive studies utilizing right heart catheterization may clarify whether pimobendan therapy causes pulmonary vasodilatation in dogs, or whether it solely improves ventricular contractility and thereby decreases LA pressure.

The NT-proBNP concentrations in dogs with PHT were increased above those of the healthy control dog population. This result is similar to what has been seen previously in other studies.a,16–18,42 Although NT-proBNP concentrations decreased significantly during the short-term phase, this effect was not maintained long term. This result differs from those of human studies in which changes in pulmonary hemodynamics paralleled changes in NT-proBNP.43 The lack of significant results potentially may be explained by the small study population, day-to-day variation in NT-proBNP concentrations (known to exist in dogs44 and humans45), or possibly progression of the underlying disease process.

An improvement in quality-of-life score as assessed by the owner was seen in the short-term comparison, but not in the long-term phase. Despite this, all owners opted to continue therapy with pimobendan after conclusion of the study. The long interval (3 months) between the initial and final visit may have affected owner's perceptions of their dog's baseline behavior. Allowing the owner to review their pet's previous FETCH questionnaire results may have aided recall.

Normal M-mode LA size is close to the aortic root size in healthy dogs, with an upper reference range of 1.13.10 As expected with the remodeling and resultant LA enlargement that occurs in chronic mitral regurgitation, all of the study dogs had a left atrium to aortic root ratio (LA/Ao) ratio >1.13 at baseline. An LA/Ao ratio >1.7 has been demonstrated to be one of the most important independent predictors of cardiac-related death in dogs.46 At baseline, 5 dogs had an LA/Ao ratio >1.7. There was no significant change in either the short-term or long-term comparison in either the size of the left atrium or the LA/Ao ratio, in contrast to another published study examining the effects of pimobendan therapy.37 If pimobendan exerts its effects by decreasing LA filling pressure, the lack of significant change in the size of the left atrium or the LA/Ao ratio may be a reflection of small sample size. Alternatively, a decrease in LA size may occur only with a large decrease in LA pressure or pimobendan could be decreasing the PHT by another mechanism.

Doppler-derived systolic time intervals of pulmonary artery flow have been studied in dogs with naturally occurring PHT.33,34 Several veterinary studies have demonstrated decreased right ventricular acceleration time and decreased acceleration time-to-ejection time ratios in dogs with PHT compared with normal. At baseline, our study dogs revealed decreased median acceleration times and decreased median acceleration time-to-ejection time ratios compared with published normal reference ranges.33,34 At day 91, both the pulmonary artery acceleration and ejection times had increased significantly. This observation may be indicative of an effect of pimobendan on the precapillary vasculature.

There was a decrease in the vertebral heart score in the short-term comparison, which has been noted in other studies.37 However, the reduction in the vertebral heart score was not maintained long term, possibly due the progressive nature of mitral valve disease.

Several limitations of this study must be acknowledged. The most important limitation was the low number of cases enrolled, particularly those with precapillary PHT. However, the 2 dogs diagnosed with precapillary PHT had either minimal change, or worsening of their results by day 91. Failure to maintain long-term improvements in NT-proBNP and quality-of-life scores may be because no actual change occurred, or there was inadequate power to detect a difference. Additionally, this study population had many different concurrently prescribed medications, which may be confounding variables. Furosemide and angiotensin converting enzymes inhibitors, however, were background therapy in all dogs.

The crossover study design allowed each patient to act as its own control during the short-term phase, minimizing intersubject variability. However, bias might have been introduced during the open-label phase. Ideally, a larger number of study subjects and a blinded long-term placebo-controlled phase should have been used. Also age and breed matching would have strengthened the comparison of the study dogs to the normal controls. ECG data did not identify any trends with pimobendan treatment. However, a more thorough evaluation of heart rate or development of arrhythmias would have required multiple 24-hour ambulatory ECG analyses. An additional limitation of this study was the lack of an echocardiographic validation study evaluating the main observer's (KJA) inter- and intraday variability.

In conclusion, this study showed that pimobendan significantly decreased the severity of PHT in MVD as estimated noninvasively using peak TRFV. This was demonstrated in the short-term comparison with placebo, and long term comparing baseline TRFV to values at completion of the study. Pimobendan may be a viable 1st line or adjunctive treatment option for dogs with PHT secondary to mitral valve disease.

Footnotes

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

aOyama MA, Rush JE, Rozanski EA, et al. NT-proBNP assay distinguishes cardiac vs. primary respiratory causes of respiratory signs in dogs. ACVIM Forum 2008, San Antonio, TX. June 4, 2008.

bVetmedin, Boehringer Ingelheim Pharma KG, Ingelheim, Germany

cVeterinary Diagnostic Institute, Irvine, CA

dNCSS Inc, Kaysville, UT

eSAS Institute Inc, Cary, NC

Acknowledgment

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References

Supported by funding from the American Kennel Club ACORN grant, the ACVIM Cardiology resident grant, and the University of Missouri Committee on Research grant.

References

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Footnotes
  7. Acknowledgment
  8. References
  • 1
    Johnson L, Boon J, Orton EC. Clinical characteristics of 53 dogs with Doppler-derived evidence of pulmonary hypertension: 1992–1996. J Vet Intern Med 1999;13:440447.
  • 2
    Serres FJ, Chetboul V, Tissier R, et al. Doppler echocardiography-derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001–2005). J Am Vet Med Assoc 2006;229:17721778.
  • 3
    Johnson L. Diagnosis of pulmonary hypertension. Clin Tech Small Anim Pract 1999;14:231236.
  • 4
    Steele JL, Henik RA. Pulmonary hypertension. In: KingL, ed. Textbook of Respiratory Disease in Dogs and Cats. St Louis, MO: WB Saunders; 2004:498503.
  • 5
    Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: Hemodynamic diagnosis and management. Arch Intern Med 2002;162:19251933.
  • 6
    MacDonald K, Johnson L. Pulmonary hypertension and pulmonary thromboembolism. In: EttingerS, FeldmanE, eds. Textbook of Veterinary Internal Medicine, 6th ed. St Louis, MO: Elsevier; 2005:12841288.
  • 7
    McLaughlin VV, Rich S. Pulmonary hypertension. Curr Probl Cardiol 2004;29:575634.
  • 8
    Johnson LR, Hamlin RL. Recognition and treatment of pulmonary hypertension. In: BonaguraJD, ed. Kirk's Current Veterinary Therapy XII. Philadelphia, PA: WB Saunders; 1995:887892.
  • 9
    Pyle RL, Abbott J, MacLean H. Pulmonary hypertension and cardiovascular sequelae in 54 Dogs. Intern J Appl Res Vet Med 2004;2:99109.
  • 10
    Boon J. Manual of Veterinary Echocardiography. Baltimore, MD: Lippincott Williams & Wilkins; 1998:179, 342–462.
  • 11
    Sisson DD. Neuroendocrine evaluation of cardiac disease. Vet Clin North Am 2004;34:11051126.
  • 12
    Lisy O, Redfield MM, Schirger JA, et al. Atrial BNP endocrine function during chronic unloading of the normal canine heart. Am J Physiol 2005;288:R158R162.
  • 13
    Maack T. The broad homeostatic role of natriuretic peptides. Arquivos brasileiros de endocrinologia e metabologia 2006;50:198207.
  • 14
    Andreassen AK, Wergeland R, Simonsen S, et al. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension. Am J Cardiol 2006;98:525529.
  • 15
    Leuchte HH, El Nounou M, Tuerpe JC, et al. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension. Chest 2007;131:402409.
  • 16
    Boswood A, Dukes-McEwan J, Loureiro J, et al. The diagnostic accuracy of different natriuretic peptides in the investigation of canine cardiac disease. J Small Anim Pract 2007;49:2632.
  • 17
    Fine DM, Declue AE, Reinero CR. Evaluation of circulating amino terminal-pro-B-type natriuretic peptide concentration in dogs with respiratory distress attributable to congestive heart failure or primary pulmonary disease. J Am Vet Med Assoc 2008;232:16741679.
  • 18
    Oyama MA, Fox PR, Rush JE, et al. Clinical utility of serum N-terminal pro-B-type natriuretic peptide concentration for identifying cardiac disease in dogs and assessing disease severity. J Am Vet Med Assoc 2008;232:14961503.
  • 19
    Pagel PS, Hettrick DA, Warltier DC. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol 1996;91:296307.
  • 20
    Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996;119:609615.
  • 21
    Ohte N, Cheng CP, Suzuki M, et al. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1997;282:2331.
  • 22
    Van Meel JC, Diederen W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharmacol 1989;14 (Suppl 2):S1S6.
  • 23
    Watanabe E, Shiga T, Matsuda N, et al. Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a patient with severe primary pulmonary hypertension. Cardiovasc Drugs Ther 2003;17:375379.
  • 24
    Nakatani M, Shirotani T, Kobayashi K, et al. Effects of low dose pimobendan in patients with cor-pulmonale. J Cardiol 1999;34:7983.
  • 25
    Yamazaki Y, Matsumoto H, Takeda A, et al. Effects of pimobendan on pulmonary hypertension in patients with chronic pulmonary emphysema. Nihon Kyobu Shikkan Gakkai Zasshi 1997;35:847853.
  • 26
    Shiga T, Wakaumi M, Yajima T, et al. Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: Report on two cases. Cardiovasc Drugs Ther 2002;16:259263.
  • 27
    Sahara M, Takahashi T, Imai Y, et al. New insights in the treatment strategy for pulmonary arterial hypertension. Cardiovasc Drugs Ther 2006;20:377386.
  • 28
    Bach JF, Rozanski EA, MacGregor J, et al. Retrospective evaluation of sildenafil citrate as a therapy for pulmonary hypertension in dogs. J Vet Intern Med 2006;20:11321135.
  • 29
    Kellum H, Stepien R. Sildenafil citrate therapy in 22 dogs with pulmonary hypertension. J Vet Intern Med 2007;21:12581264.
  • 30
    O'Sullivan M. Pulmonary hypertension. In: MathewsK, ed. Veterinary Emergency and Critical Care Manual. Guelph, ON: Lifelearn; 2006:189193.
  • 31
    Schmidt MK, Reynolds CA, Estrada AH, et al. Effect of azotemia on serum N-terminal proBNP concentration in dogs with normal cardiac function: A pilot study. J Vet Cardiol 2009;11:S81S86.
  • 32
    Thomas W, Gaber C, Jacobs G, et al. Recommendations for standards in tranthoracic two-dimensional echocardiography in the dog and cat. Vet Radiol Ultrasound 1994;35:173178.
  • 33
    Serres F, Chetboul V, Gouni V, et al. Diagnostic value of echo-Doppler and tissue Doppler imaging in dogs with pulmonary arterial hypertension. J Vet Intern Med 2007;21:12801289.
  • 34
    Schober KE, Baade H. Doppler echocardiographic prediction of pulmonary hypertension in West Highland White Terriers with chronic pulmonary disease. J Vet Intern Med 2006;20:912920.
  • 35
    Tilley LP. Essentials of Canine and Feline Electrocardiography, 3rd ed. Philadelphia, PA: Lea & Febiger; 1992, p.172.
  • 36
    Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194199.
  • 37
    Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249261.
  • 38
    Freeman LM, Rush JE, Farabaugh AE, et al. Development and evaluation of a questionnaire for assessing health-related quality of life in dogs with cardiac disease. J Am Vet Med Assoc 2005;226:18641868.
  • 39
    Häggström J, Boswood A, O'Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: The QUEST study. J Vet Intern Med 2008;22:11241135.
  • 40
    Hatle L, Angelson B. Doppler Ultrasound in Cardiology: Physical Principles and Clinical Application. Philadelphia, PA: Lea & Febiger; 1982:113116.
  • 41
    O'Callaghan DS, McNeil K. Pulmonary hypertension and left heart disease: Emerging concepts and treatment strategies. Int J Clin Pract 2008;62:2931.
  • 42
    Tarnow I, Olsen LH, Kvart C, et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009;180:195201.
  • 43
    Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. Eur Respir J 2006;28:11901194.
  • 44
    Kellihan HB, Oyama MA, Reynolds CA, Stepien RL. Weekly variability of plasma and serum NT-proBNP measurements in normal dogs. J Vet Cardiol 2009;11:S93S97.
  • 45
    O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variation of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007;13:5055.
  • 46
    Borgarelli M, Savarino P, Crosara S, et al. Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease. J Vet Intern Med 2008;22:120128.